- Yaky Yanay appointed Co-Chief Executive Officer to serve together with Co-Chief Executive Officer Zami Aberman
- Erez Egozi appointed as Chief Financial Officer
Cynata Therapeutics Lands Japanese Giant Fujifilm
It is not every day that an Aussie minnow lands a deal with a Japanese whale. When Fujifilm took a 9% equity stake in Cynata Therapeutics Ltd (ASX: CYP), it was a major lift for the regenerative medicine company, positioning Cynata to benefit not only from Fujifilm’s resources but also more broadly from current economic strategy within Japan.
Prime Minister of Japan, Shinzō Abe, has committed to building leadership around a new generation of regenerative medicine products involving human cells and tissues and Cynata is now perfectly positioned to take advantage of this in the world’s second largest market for healthcare products. [Read more…]
Cynata Inks Deal with FUJIFILM, $3.97M Plus Potential Payments of $60M+
Cynata and FUJIFILM Sign Development and Commercialisation Partnership Agreement
- Fujifilm takes A$3.97 million strategic equity stake in Cynata
- Parties to collaborate on the further development and commercialisation of Cynata’s lead Cymerus™ therapeutic MSC product CYP-001 for graft-versus-host disease (GvHD)
- Potential future upfront and milestone payments in excess of A$60 million
- Double-digit royalties on CYP-001 product net sales
- Strategic relationship for potential future manufacture of CYP-001 and certain rights to other Cynata technology
MD Anderson and NIH to Fund Clinical Trial Combining 2 Mesoblast Technologies
On December 6th, MD Anderson Cancer Center and NIH announced that they will be funding a clinical trial that will combine two Mesoblast technologies:
- Mesenchymal Precursor Cell (MPC)-based expansion
- Ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients
The purpose of the trial is to provide clinical data to indicate whether these technologies can interact synergistically to promote faster cord blood HSC engraftment for bone marrow transplant patients. [Read more…]
Global Cooperation – MD Anderson and NIH to Fund Clinical Trial Combining Mesoblast Technologies
MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients
New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transpl
antation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.
The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- Next Page »